Clinical Trial Update: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of ImmunityBio's NANT TNBC vaccine (QUILT-3.067) for triple-negative breast cancer that progressed after standard therapy was terminated; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• NANT TNBC Vaccine

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-09